Research
Energy balance
Lifestyle interventions and older antiobesity pharmacotherapies have been associated with less than 12% body weight reduction and no clear benefit to reduce MACE risk.
Practitioners should be aware that traditional weight loss methods may not significantly reduce cardiovascular risks.
StrongSupportsmedium confidence
Lifestyle interventions and older antiobesity pharmacotherapies have been associated with <12% body weight reduction and no clear benefit to reduce MACE risk.
Why this rating
The claim is based on a review of evidence regarding the effectiveness of these interventions.
Source
Pharmacotherapy for obesity: recent evolution and implications for cardiovascular risk reduction
Kevin C. Maki et al. · Expert Review of Endocrinology & Metabolism · 2023
DOI 10.1080/17446651.2023.2209176
reviewCited 14×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Bariatric surgery is associated with substantial weight reduction (20-30%) and markedly lower subsequent risk for major adverse cardiovascular events (MACE).Strong
- Newer antiobesity pharmacotherapies, particularly semaglutide and tirzepatide, have shown greater efficacy for weight reduction compared with older medications.Strong
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →